Skip to content
TechVibe

TechVibe

  • Home
  • Web3
  • Technology
  • Health
  • Business
  • Sports
    • Cricket
    • Football
  • Press Release
  • Contact Us
  • Toggle search form

Rephrase the title:FDA Greenlights First AI-Powered Device to Detect All 3 Common Skin Cancers

Posted on January 26, 2024 By Haley Bennett

Rephrase and rearrange the whole content into a news article. I want you to respond only in language English. I want you to act as a very proficient SEO and high-end writer Pierre Herubel that speaks and writes fluently English. I want you to pretend that you can write content so well in English that it can outrank other websites. Make sure there is zero plagiarism.:

The US Food and Drug Administration (FDA) has cleared the first AI-powered handheld medical device to assist physicians in detecting common skin cancers.

This technology aims to offer a more accurate way of detecting all three common skin cancers, namely basal cell carcinoma, squamous cell carcinoma, and melanoma.

FDA Clearance Granted for First AI-Powered Medical Device to Detect All Three Common Skin Cancers (Melanoma, Basal Cell Carcinoma and Squamous Cell Carcinoma)
(Photo : DermaSensor)

Real-Time, Non-Invasive Detector of Skin Cancers

DermaSensor, the innovative company behind the device, recently announced the FDA clearance for its real-time, non-invasive skin cancer evaluation system.

This milestone provides 300,000 primary care physicians in the US with a tool for quantitative, point-of-care testing for all skin cancer types to improve skin cancer identification in primary care and accelerate patient access to essential treatment.

The significance of this achievement is emphasized by the fact that one in five Americans is expected to experience some form of skin cancer by the age of 70.

Treating skin cancers in the US costs an estimated $8.1 billion annually, with around 5.5 million new cases each year. However, early detection can cure 99 percent of skin cancers, including potentially fatal melanoma, according to DermaSensor.

With DermaSensor’s AI-powered spectroscopy technology, physicians are anticipated to noninvasively evaluate suspicious skin lesions for cancer. The wireless handheld device is expected to deliver an unbiased result using an FDA-cleared algorithm.  

FDA Study

Findings from an FDA study with over 1,000 patients led by the Mayo Clinic across 22 study centers highlighted the device’s impressive performance. 

The study demonstrated a sensitivity of 96 percent across all 224 skin cancers, while a negative result indicated a 97 percent likelihood of the lesion being benign for all skin cancers. 

In a companion clinical utility study involving 108 physicians, the DermaSensor device effectively halved missed skin cancer cases, enhancing physicians’ accuracy and confidence in evaluating cancerous lesions.

Cody Simmons, co-founder and Chief Executive Officer of DermaSensor, commented on the transformative impact of artificial intelligence in healthcare, especially when coupled with advanced technologies like spectroscopy and genetic sequencing. 

Simmons expressed pride in the first FDA-cleared device, which offers primary care physicians an automated tool for evaluating suspicious lesions. 

Read Also: Moderna, Merck’s Groundbreaking Melanoma Treatment Shows Promise in Combination Therapy Study

Medical Milestone

The advantages of this innovation reach beyond primary care physicians to dermatologists, fostering enhanced collaboration between the two fields. 

DermaSensor is positioned to improve coordination between primary care and dermatology, streamlining prioritized referrals and increasing the number of referrals for patients with skin cancer.  

“Achieving this medical milestone is a testament to the 12 years and tens of millions of dollars our company has invested in research and development to bring this powerful technology to market,” said Dr. Maurice Ferre, co-founder and chairman of DermaSensor. 

“We are incredibly grateful to the FDA for their collaboration and dedication to this area starting with our first FDA pre-submission meeting in 2016. Having begun patient enrollment in our FDA pivotal study in mid-2020, we are now ecstatic to have clearance of our FDA-Breakthrough Designated De Novo submission,” he added. 

Related Article: World’s Smallest Skin Cancer Now a Guinness World Record! Almost Invisible to the Naked Eye

Byline

ⓒ 2023 TECHTIMES.com All rights reserved. Do not reproduce without permission.

Haley Bennett

I have over 10 years of experience in the cryptocurrency industry and I have been on the list of the top authors on LinkedIn for the past 5 years. I have a wealth of knowledge to share with my readers, and my goal is to help them navigate the ever-changing world of cryptocurrencies.

Health Tags:AI, Artificial Intelligence, Cancer, fda, Food and Drug Administration, Skin cancer, U.S. Food and Drug Administration, US Food and Drug Administration

Post navigation

Previous Post: Rephrase the title:iOS 17.4 Beta Adds 118 New Emoji. The Phoenix One Is Fire.
Next Post: Rephrase the title:Sharjah Cricket Stadium, UAE: Pitch report, records and highest scores in T20s ahead of ILT20 clash between Sharjah Warriors and MI Emirates

Related Posts

Rephrase the title:CES 2024 Showcasing Revolutionizing Tech: AI in Mobility, Concept Cars, and Game-Changing Gadgets Health
Rephrase the title:Bereans, Inc: Pioneering the Future of Off-Grid Living Through Technological Innovation Health
Rephrase the title:TikTok vs. Universal Music: Songs by Top Artists Like Taylor Swift Will No Longer Be Available on TikTok Health
Rephrase the title:Jeff Bezos, Nvidia Join Forces in $675M Investment for Humanoid Robots Health
Rephrase the title:Instagram Surpasses TikTok in App Downloads, Riding High on Short-Form Video Trend Health
Rephrase the title:Solar-Powered Eyes? Australian Scientists Are Working on Implanting Tiny Solar Panels Into People’s Eyeballs Health

Recent Posts

  • Robin Open Social-Fi: Revolutionizes Gaming with Innovative Integration and Global Partnerships
  • $GUMMY Set to Launch New Meta On Staking on Solana
  • BinoStake.io: Transforming Crypto Investments On BNB Chain with Liquid Staking Solutions
  • Mocaverse to Develop Decentralized Social Layer
  • Expansion of Web3 Fueled by Hong Kong’s Financial Secretary

Categories

  • Business
  • Cricket
  • Football
  • Health
  • Press Release
  • Technology
  • Web3

About Us

Welcome to TechVibe9, where the rhythm of technology meets innovation! We are a group of tech enthusiasts on a mission to uncover and showcase the latest in the tech world.

Mail Us : support@techvibe9.com

Latest Post

  • Robin Open Social-Fi: Revolutionizes Gaming with Innovative Integration and Global Partnerships
  • $GUMMY Set to Launch New Meta On Staking on Solana
  • BinoStake.io: Transforming Crypto Investments On BNB Chain with Liquid Staking Solutions

Helpful Links

  • About Us
  • Contact Us
  • Privacy Policy
  • Terms & Conditions

Copyright © TechVibe9

Powered by PressBook Masonry Dark